Atara Biotherapeutics Inc - Asset Resilience Ratio
Atara Biotherapeutics Inc (ATRA) has an Asset Resilience Ratio of 26.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Atara Biotherapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Atara Biotherapeutics Inc's Asset Resilience Ratio has changed over time. See Atara Biotherapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Atara Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Atara Biotherapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.97 Million | 26.42% |
| Total Liquid Assets | $7.97 Million | 26.42% |
Asset Resilience Insights
- Very High Liquidity: Atara Biotherapeutics Inc maintains exceptional liquid asset reserves at 26.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atara Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Atara Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Atara Biotherapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Atara Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.01% | $17.47 Million | $109.10 Million | +0.37pp |
| 2023-12-31 | 15.64% | $25.88 Million | $165.50 Million | -24.18pp |
| 2022-12-31 | 39.82% | $149.88 Million | $376.42 Million | -16.79pp |
| 2021-12-31 | 56.61% | $264.98 Million | $468.13 Million | +5.55pp |
| 2020-12-31 | 51.05% | $300.25 Million | $588.12 Million | -2.83pp |
| 2019-12-31 | 53.88% | $184.79 Million | $342.94 Million | -9.65pp |
| 2018-12-31 | 63.53% | $248.93 Million | $391.84 Million | +23.64pp |
| 2017-12-31 | 39.89% | $86.87 Million | $217.78 Million | -38.81pp |
| 2016-12-31 | 78.71% | $207.71 Million | $263.91 Million | -12.61pp |
| 2015-12-31 | 91.31% | $296.74 Million | $324.98 Million | +13.83pp |
| 2014-12-31 | 77.48% | $82.22 Million | $106.12 Million | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more